Algaeon Inc. (Indianapolis) announced the signing of a multiyear, multimillion-dollar supply agreement with Valensa International (Eustis, Fla.), which provides high value “condition-specific” nutraceuticals to the marketplace. Algaeon, in cooperation with Valensa, is using its extensive knowledge of algae production to bring a new level of efficiency and quality for algae-based ingredient supply to the nutraceutical market. Algaeon will develop manufacturing and technology processes while Valensa will produce finished form condition specific products that will be sold to marketers with recognized brands. Valensa’s ingredient and formulation portfolio currently includes high quality algae-based products such as Zanthin® brand Astaxanthin, Parry Organic Spirulina, SpiruZan® (astaxanthin + spirulina) tablets and phycocyanin-coated Pur-Blue™SpiruZan®.
“Algaeon is thrilled to be working together with Valensa, a global leader in nutraceutical formulation for the human supplement market, and we are looking forward to bringing our exciting technology to the market,” said Paul DeLacey, chairman and CEO of Algaeon Inc. “We are confident that our combined strengths will allow us to move quickly and make a significant impact on the ‘conditio-specific’ nutraceutical market.”
According to Dr. Rudi E. Moerck, president and CEO of Valensa, the algae technology relationship with Algaeon provides a significant additional supplier of algae biomass and extracts to Valensa to allow the company to grow its portfolio of advanced condition-specific products. “Valensa is a rapidly growing nutraceutical company with a thriving astaxanthin-based, condition-specific formulation business,” said Moerck. “We are excited and confident that this collaboration with Algaeon will provide additional algae sourced ingredients to Valensa to ultimately expand its offerings beyond Spirulina and Astaxanthin. We share Algaeon’s vision and commitment to delivering high quality algae products for improved human health to the market,” he added.